1-(3-Fluoropropyl)azetidin-3-amine ethane-1,2-disulfonateis a pharmaceutical intermediate typically used as starting material in the preparation of GDC-9545 as an orally active and selective estrogen receptor (ER) antagonist for the treatment of cancer.
Abstract P5-04-07: GDC-9545: A novel ER antagonist and clinical candidate that combines desirable mechanistic and pre-clinical DMPK attributes. 
 C.Metcalfe, et al, 2018 San Antonio Breast Cancer Symposium, December 4-8, San Antonio, Texas.
NONH for all modes of transport
1. Product Specification
2. Safety Data Sheet
Please inquire for pricing and availability of this product by writing email firstname.lastname@example.org.